Mitiglinide calcium hydrate
An insulin secretion stimulator by closing the ATP-sensitive potassium KATP channels in pancreatic β cells; has potent hypoglycemic effects.Diabetes Approved (In Vitro) :Mitiglinide calcium hydrate inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 μM) in COS-1 cells. (In Vivo) :Mitiglinide Calcium hydrate (1-3 mg/kg; p.o.) suppresses the increase in plasma glucose levels seen after a meal load and the area under the curve for plasma glucose levels (AUCglucose) up to 5 h after the meal load.
Product Specifications
CAS Number
207844-01-7
Product Name Alternative
KAD-1229 calcium hydrate | S-21403 calcium hydrate
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
10 mM in DMSO
Smiles
C1CC[C@H]2CN (C[C@H]2C1) C (=O) C[C@H] (CC3=CC=CC=C3) C (=O) [O-].C1CC[C@H]2CN (C[C@H]2C1) C (=O) C[C@H] (CC3=CC=CC=C3) C (=O) [O-].O.O.[Ca+2]
Molecular Formula
C19H25NO3 . 1/2 Ca . H2O
Molecular Weight
353.46
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
2H-Isoindole-2-butanoic acid, octahydro-γ-oxo-α- (phenylmethyl) -, calcium salt, hydrate (2:1:2), (αS,3aR,7aS) -
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Quaternary ammonium compound-resistance protein sugE (sugE)
Recombinant Quaternary ammonium compound-resistance protein sugE (sugE)
Recombinant Quaternary ammonium compound-resistance protein sugE (sugE)